Secukinumab Rapidly Improves EQ-5D Health Status in Patients With Psoriasis: Pooled Analysis From Four Phase 3 Trials.
Conclusion: These findings provide additional evidence of the quality-of-life impairment in patients with moderate-to-severe psoriasis and highlight the improvement across all EQ-5D-3L domains among patients treated with secukinumab.
PMID: 31873050 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Anxiety | Clinical Trials | Depression | Dermatology | Men | Pain | Psoriasis | Psychology | Skin